Back to Newsroom
Back to Newsroom

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of DOX, DNMR and FREQ

Monday, 07 June 2021 02:40 PM

The Gross Law Firm

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / June 7, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Amdocs Limited (NASDAQ:DOX)

Investors Affected : December 13, 2016 - March 30, 2021

A class action has commenced on behalf of certain shareholders in Amdocs Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs’ reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/amdocs-limited-loss-submission-form/?id=16629&from=1

Danimer Scientific, Inc. (NYSE:DNMR)

Investors Affected : October 5, 2020 - May 4, 2021

A class action has commenced on behalf of certain shareholders in Danimer Scientific, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Danimer had deficient internal controls; (ii) as a result, the Company had misrepresented, inter alia, its operations’ size and regulatory compliance; (iii) Defendants had overstated Nodax’s biodegradability, particularly in oceans and landfills; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/danimer-scientific-inc-loss-submission-form/?id=16629&from=1

Frequency Therapeutics, Inc. (NASDAQ:FREQ)

Investors Affected : November 16, 2020 - March 22, 2021

A class action has commenced on behalf of certain shareholders in Frequency Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company’s Phase 2a trial results failed to live up to the Company’s expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322’s potential. These statements materially misled the market and artificially inflated the value of Frequency’s common stock.

Shareholders may find more information at https://securitiesclasslaw.com/securities/frequency-therapeutics-inc-loss-submission-form/?id=16629&from=1

The Gross Law Firm, Monday, June 7, 2021, Press release picture

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: